Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase IV Study for the Assessment of Modulating Effect of Galantamine (Reminyl PRC) on Circadian Rhythm in Patients With Moderate Alzheimer's Disease

NCT01181921 is registered in ClinicalTrials.gov with Janssen-Cilag, S.A. as lead sponsor.

NCT NCT01181921
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01181921 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase IV Study for the Assessment of Modulating Effect of Galantamine (Reminyl PRC) on Circadian Rhythm in Patients With Moderate Alzheimer's Disease
Lead sponsor
Janssen-Cilag, S.A.
Phase
Phase 4
Overall status
Terminated
Start date
May 31, 2011
Completion date
June 30, 2011
Enrollment
1 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease